|
| 从气阴两虚探讨补肺汤治疗化疗后肺气阴虚证肺部非小细胞癌的临床观察 |
| Clinical Observation on the Treatment of Non-Small Cell Lung Cancer with Lung Qi and Yin Deficiency Syndrome after Chemotherapy by Bu Fei Decoction: A Study from the Perspective of Qi and Yin Deficiency |
| 投稿时间：2025-01-14 修订日期：2025-01-14 |
| 中文关键词: 补肺汤 肺部非小细胞癌 气阴两虚证 化疗 |
| 英文关键词: |
| 基金项目: |
|
| 摘要点击次数: 48 |
| 全文下载次数: 0 |
| 中文摘要: |
| 【】目的:分析运用补肺汤对化疗后肺气阴虚证的肺部非小细胞癌(non-small-cell lung cancer,NSCLC)患者的临床疗效和对其生活质量的影响。方法:收集2019年6月至2023年12月确诊为NSCLC化疗后辨证为肺气阴虚证患者,对照组为基础治疗患者或拒绝服用中药患者；观察组为服用补肺汤患者,比较两组患者的一般资料,包括性别、年龄、吸烟史、肿瘤家族史、病理类型、临床分期、化疗药物史、口服中药时间,不良反应发生率、复发率,生活质量评分(Quality of Life,QOL)、Karnofsky(KPS)评分、中医证候评分等。结果:与对照组相比,观察组死亡率(10.71%)、复发率(7.73%)不良反应发生率(31.55%)均下降,差异具有统计学意义(p＜0.05),与对照组相比,观察组QOL评分升高,差异具有统计学意义(p＜0.01)；与对照组相比,观察组KPS评分较高,差异统计学意义(p＜0.01),说明与不服用中药的患者相比,口服补肺汤的患者健康状况和生活质量有所改善,两组患者在治疗后中医症状均有所好转,但与对照组相比,观察组的倦怠乏力、咳嗽咯痰、喘促气急、潮热盗汗相关症状明显改善,差异统计学意义(p＜0.01)。结论:补肺汤能提高化疗后肺气阴虚证的NSCLC患者的生活质量和健康水平,降低其死亡率、复发率及不良反应发生率,在临床值得推广。 |
| 英文摘要: |
| Objective: To analyze the clinical efficacy of Bu Fei Decoction in treating non-small cell lung cancer (NSCLC) patients with lung qi and yin deficiency syndrome after chemotherapy and its impact on their quality of life. Methods: Patients diagnosed with NSCLC and identified as having lung qi and yin deficiency syndrome after chemotherapy from June 2019 to December 2023 were collected. The control group consisted of patients receiving only basic treatment or those who refused to take traditional Chinese medicine. The observation group included patients taking Bu Fei Decoction. General data of the two groups were compared, including gender, age, smoking history, family history of tumors, pathological type, clinical stage, history of chemotherapy drugs, duration of oral traditional Chinese medicine, incidence of adverse reactions, recurrence rate, quality of life (QOL) score, Karnofsky Performance Status (KPS) score, and TCM syndrome score. Results: Compared with the control group, the mortality rate (10.71%), recurrence rate (7.73%), and incidence of adverse reactions (31.55%) in the observation group were all decreased, with statistically significant differences (p < 0.05). Compared with the control group, the QOL score in the observation group increased, with statistically significant differences (p < 0.01). Compared with the control group, the KPS score in the observation group was higher, with statistically significant differences (p < 0.01). This indicates that compared with patients not taking traditional Chinese medicine, those taking Bu Fei Decoction had improved health status and quality of life. Both groups showed improvement in TCM symptoms after treatment, but compared with the control group, the observation group had significantly improved symptoms related to fatigue, cough with phlegm, shortness of breath, and night sweats, with statistically significant differences (p < 0.01). Conclusion: Bu Fei Decoction can improve the quality of life and health status of NSCLC patients with lung qi and yin deficiency syndrome after chemotherapy, reduce their mortality rate, recurrence rate, and incidence of adverse reactions, and is worthy of promotion in clinical practice. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
